The Current Standard-of-Care for Patients with HER2+ Metastatic Breast Cancer
October 6th 2022Neil M. Iyengar, MD briefly reviews the standard-of-care first-line treatment for patients with metastatic HER2+ breast cancer as well as historical approaches to progression after first-line treatment.
Read More
Patient Profile 1: Sequencing Therapies in HER2+ mBC
April 15th 2022Shared insights on the use of therapies as a patient progresses with HER2+ metastatic breast cancer, which includes sequencing through T-DM1 [trastuzumab emtansine], tucatinib/capecitabine/trastuzumab, and trastuzumab deruxtecan.
Read More
Treatment Advances in HR+/HER2- MBC
Final takeaways from a discussion on best practices treating HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors and PI3K therapies based on data presented at ESMO 2021.
Read More
Managing Patients With HR+ MBC on PI3K Therapy
Breast oncologists share pearls regarding best practices treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitor therapy and mitigating treatment-related adverse events.
Read More
PI3K Inhibitors for PIK3CA-Mutated HR+ MBC
Considerations for treating patients with HR+/HER2- metastatic breast cancer with alpelisib, a PI3K inhibitor, following frontline treatment with a CDK4/6 inhibitor.
Read More
CDK4/6 Treatment Selection for HR+/HER2- MBC
The impact of recent data presented at ESMO 2021 in terms of selecting an appropriate CDK4/6 inhibitor as first-line treatment of HR+/HER2- metastatic breast cancer.
Read More